Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CLLS
CLLS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CLLS News
Cellectis Presents Final Phase 1 Data from BALLI-01 Trial
Jun 11 2026
Newsfilter
Cellectis CAR-T Therapy Receives FDA RMAT Designation
Jun 10 2026
seekingalpha
Cellectis Receives FDA RMAT Designation, Stock Soars
Jun 09 2026
stocktwits
Cellectis Receives FDA RMAT Designation for CAR-T Therapy
Jun 09 2026
Newsfilter
Cellectis to Hold Annual General Meeting on June 25, 2026
May 20 2026
Newsfilter
Cellectis Reports Q1 2026 Financial Results and Business Update
May 11 2026
Newsfilter
Cellectis to Report Q1 2026 Financial Results on May 11
May 04 2026
Newsfilter
Cellectis Highlights Allogene's Pivotal Trial Progress
Apr 13 2026
Newsfilter
Cellectis SA Reports 2025 Financial Results and Clinical Updates
Mar 20 2026
Yahoo Finance
Cellectis to Announce Q4 Earnings on March 19
Mar 18 2026
seekingalpha
Cellectis Initiates Pivotal Trials for Lasme-cel and Eti-cel, 2026 Outlook Positive
Jan 08 2026
Globenewswire
Autolus Evaluates Cellares' Automated Platform for Manufacturing Expansion
Jan 06 2026
Newsfilter
Cellectis SA Receives Buy Rating with $9 Price Target from Clear Street
Dec 23 2025
Benzinga
Cellectis Shares Under Pressure Following Allogene Arbitration Win on Tuesday
Dec 16 2025
Benzinga
Lightwave Logic, Kyverna Therapeutics, and Other Major Stocks Decline in Tuesday's Pre-Market Trading
Dec 16 2025
Benzinga
Allogene Secures Global Control of Cema-Cel, Interim Analysis Set for 1H 2026
Dec 15 2025
Globenewswire
Show More News
